Heparin Dosing During Coronary Artery Stenting
For patients undergoing coronary artery stenting, administer an initial unfractionated heparin bolus of 70-100 U/kg IV to achieve a target activated clotting time (ACT) of 250-300 seconds, and discontinue heparin immediately after the procedure without routine post-procedural infusion.
Intraprocedural Heparin Dosing
Standard Dosing Without Glycoprotein IIb/IIIa Inhibitors
The recommended initial bolus is 70-100 U/kg IV for patients not receiving glycoprotein IIb/IIIa inhibitors, targeting an ACT of 250-300 seconds 1, 2, 3. The 2025 ACC/AHA guidelines specify this dosing for patients undergoing PCI who have not received prior anticoagulant therapy 4. The FDA-approved dosing for cardiovascular surgery includes 150 units/kg minimum, with 300 units/kg for procedures under 60 minutes 5.
- Monitor ACT hourly during the procedure and administer supplemental heparin boluses (typically 2,000-5,000 U) as needed to maintain therapeutic ACT 3.
- The target ACT range of 250-300 seconds is based on evidence showing higher complication rates with lower ACT values 6, 7.
Reduced Dosing With Glycoprotein IIb/IIIa Inhibitors
When using glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, or tirofiban), reduce the heparin bolus to 50-70 U/kg targeting an ACT of approximately 200 seconds 1, 2, 3. This reduced dosing strategy decreases bleeding risk without compromising efficacy 6, 7.
- The 2012 ESC guidelines specify 50-60 U/kg with GP IIb/IIIa inhibitors 1.
- Remove arterial sheaths when ACT falls below 150-180 seconds to minimize bleeding complications 6, 7.
Dosing Considerations for Obesity
Obese patients require lower weight-adjusted heparin doses to achieve target ACT levels 8. A 2024 study demonstrated significant variability in heparin response, with only 49% of patients achieving target ACT with standard 70-100 U/kg dosing 8.
- Mean dose required was 103.9 ± 32 U/kg to achieve ACT ≥250 seconds 8.
- Body mass index was the only significant covariate affecting heparin dose-response after weight-based dosing 8.
Post-Procedural Heparin Management
Routine Post-Stenting Care
Discontinue heparin immediately after successful coronary stenting; routine post-procedural heparin infusion is not recommended and increases bleeding risk without reducing ischemic events 9. The 2025 ACC/AHA guidelines explicitly recommend discontinuation of parenteral anticoagulation immediately after the invasive procedure 4.
- After uncomplicated coronary intervention, continued heparin therapy provides no additional benefit and clearly increases bleeding complications 6, 10.
- A 2007 study in stented patients showed post-procedural heparin increased bleeding and hospitalization costs without decreasing major adverse cardiac events 11.
Exceptions Requiring Post-Procedural Heparin
Consider post-procedural heparin infusion (maintaining aPTT 1.5-2.3 times control) for 24 hours only in high-risk situations 9:
- Angiographically visible dissections
- Mural thrombosis
- Progressive or new ischemic symptoms
- No-reflow or slow flow phenomena
Alternative: Subcutaneous enoxaparin 1 mg/kg twice daily may be used instead of IV heparin in these high-risk scenarios 9.
Antiplatelet Therapy Transition
Continue dual antiplatelet therapy (aspirin 325 mg daily plus clopidogrel 75 mg twice daily or equivalent P2Y12 inhibitor) for at least 4 weeks after stenting, as this regimen eliminates the need for post-procedural heparin 9.
- The combination of aspirin and ticlopidine/clopidogrel has a synergistic effect and provides adequate antithrombotic coverage post-stenting 9.
- Most thromboembolic events occur postoperatively, emphasizing the importance of antiplatelet therapy rather than continued heparin 9.
Monitoring Requirements
Measure ACT at baseline, hourly during the procedure, and before sheath removal 3, 5. For post-procedural heparin (when indicated), monitor aPTT every 4 hours initially, then at appropriate intervals to maintain 1.5-2.0 times control (approximately 50-70 seconds) 12, 5.
- Periodically monitor platelet counts, hematocrit, and occult blood in stool during heparin therapy regardless of route 5.
- The 2022 ACC/AHA/SCAI guidelines emphasize selecting anticoagulation according to both ischemic and bleeding risks 13.
Common Pitfalls to Avoid
Do not administer UFH to patients already receiving therapeutic subcutaneous enoxaparin within 12 hours of PCI, as this significantly increases bleeding risk 2, 3. If the last enoxaparin dose was 8-12 hours prior or only one dose was given, administer 0.3 mg/kg IV enoxaparin instead 4, 3.
Avoid routine high-dose heparin regimens (>100 U/kg) in the modern era of dual antiplatelet therapy, as this increases bleeding without improving outcomes 14, 10. The ISAR-REACT 3A trial demonstrated that reducing heparin from 140 U/kg to 100 U/kg improved net clinical outcomes primarily by reducing bleeding 14.